NEW YORK -- Four New York shops remain in the running to handle ad duties on FluMist, a new flu vaccine from Wyeth Laboratories and MedImmune that will be delivered as a nasal spray, sources said.
The shops are Foote, Cone & Belding, McCann-Erickson, Saatchi & Saatchi and Euro RSCG MVBMS Partners, said sources. Final presentations are scheduled for the week of Oct. 14, with a decision shortly thereafter.
Billings have not been determined but sources estimated that the client would spend $30-40 million to launch the brand. The agencies either declined comment or could not be reached.
MedImmune in Gaithersburg, Md. holds licensing rights to the drug, which is still being reviewed by the U.S. Food and Drug Administration. MedImmune, in turn, has a marketing agreement with Wyeth in Wayne, Pa.
The review is being managed by AAR Partners in New York.